{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:45:03Z","timestamp":1757778303995,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01GD9820\/0"],"award-info":[{"award-number":["01GD9820\/0"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pitzer Foundation"},{"name":"Waldburg-Zeil Clinics"},{"DOI":"10.13039\/501100008977","name":"Universit\u00e4t Ulm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008977","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to describe the characteristics and mortality of two cohorts of patients with chronic coronary syndrome (CCS) recruited with identical study designs in the same rehabilitation clinics but approximately 10\u00a0years apart.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The KAROLA cohorts included patients with CCS participating in an inpatient cardiac rehabilitation programme in Germany (KAROLA-I: years 1999\/2000, KAROLA-II: 2009\u20132011). Blood samples and information on sociodemographic factors, lifestyle, and medical treatment were collected at baseline, at the end of rehabilitation, and after one year of follow-up. A biomarker-based risk model (ABC-CHD model) and Cox regression analysis were used to evaluate cardiovascular (CV) and non-CV mortality risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 1130 patients from KAROLA-I (mean age 58.7\u00a0years, 84.4% men) and 860 from KAROLA-II (mean age 60.4\u00a0years, 83.4% men). Patients in the KAROLA-I cohort had significantly higher concentrations of CV biomarkers and fewer patients were taking CV medications, except for statins. The biomarker-based ABC-CHD model provided a higher estimate of CV death risk for patients in the KAROLA-I cohort (median 3-year risk, 3.8%) than for patients in the KAROLA-II cohort (median 3-year risk, 2.7%, p-value for difference\u2009&lt;\u20090.001). After 10\u00a0years of follow-up, 91 (8.1%) patients in KAROLA-I and 45 (5.2%) in KAROLA-II had died from a CV event.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Advances in disease management over the past 20\u00a0years may have led to modest improvements in pharmacological treatment during cardiac rehabilitation and long-term outpatient care for patients with CCS. However, modifiable risk factors such as obesity have increased in the more recent cohort and should be targeted to further improve the prognosis of these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-023-03469-4","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T16:04:47Z","timestamp":1693325087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Medical care and biomarker-based assessment of mortality in two cohorts of patients with chronic coronary syndrome 10\u00a0years apart"],"prefix":"10.1186","volume":"23","author":[{"given":"Martin","family":"Rehm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Jaensch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Sch\u00f6ttker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Mons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Hahmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Rothenbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"3469_CR1","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315\u201381.","journal-title":"Eur Heart J"},{"key":"3469_CR2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.113.004042","volume":"129","author":"AE Moran","year":"2014","unstructured":"Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJL, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation. 2014;129:1483\u201392.","journal-title":"Circulation"},{"key":"3469_CR3","unstructured":"Statistisches Bundesamt Deutschland - GENESIS-Online. 2021. https:\/\/www-genesis.destatis.de\/genesis\/online?operation=statistic&levelindex=0&levelid=1625476397134&code=23211#abreadcrumb. Accessed 5 Jul 2022."},{"key":"3469_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby P. The changing landscape of atherosclerosis. Nature. 2021;592:524\u201333.","journal-title":"Nature"},{"key":"3469_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41:407\u201377.","journal-title":"Eur Heart J"},{"key":"3469_CR6","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1177\/2047487319846715","volume":"26","author":"X Rossello","year":"2019","unstructured":"Rossello X, Dorresteijn JA, Janssen A, Lambrinou E, Scherrenberg M, Bonnefoy-Cudraz E, et al. Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur J Prev Cardiol. 2019;26:1534\u201344.","journal-title":"Eur J Prev Cardiol"},{"key":"3469_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jacc.2017.06.030","volume":"70","author":"D Lindholm","year":"2017","unstructured":"Lindholm D, Lindb\u00e4ck J, Armstrong PW, Budaj A, Cannon CP, Granger CB, et al. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. J Am Coll Cardiol. 2017;70:813\u201326.","journal-title":"J Am Coll Cardiol"},{"key":"3469_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/HJR.0b013e3280142a02","volume":"14","author":"D Rothenbacher","year":"2007","unstructured":"Rothenbacher D, Hahmann H, W\u00fcsten B, Koenig W, Brenner H. Symptoms of anxiety and depression in patients with stable coronary heart disease: prognostic value and consideration of pathogenetic links. Eur J Cardiovasc Prev Rehabil. 2007;14:547\u201354.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"3469_CR9","first-page":"141","volume":"5","author":"OO Aalen","year":"1978","unstructured":"Aalen OO, Johansen S. An Empirical Transition Matrix for Non-Homogeneous Markov Chains Based on Censored Observations. Scand J Stat. 1978;5:141\u201350.","journal-title":"Scand J Stat"},{"key":"3469_CR10","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1177\/2047487316671181","volume":"23","author":"B Rauch","year":"2016","unstructured":"Rauch B, Davos CH, Doherty P, Saure D, Metzendorf M-I, Salzwedel A, et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies \u2013 The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol. 2016;23:1914\u201339.","journal-title":"Eur J Prev Cardiol"},{"key":"3469_CR11","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/eurheartj\/ehv111","volume":"36","author":"H de Vries","year":"2015","unstructured":"de Vries H, Kemps HMC, van Engen-Verheul MM, Kraaijenhagen RA, Peek N. Cardiac rehabilitation and survival in a large representative community cohort of Dutch patients. Eur Heart J. 2015;36:1519\u201328.","journal-title":"Eur Heart J"},{"key":"3469_CR12","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1161\/CIRCULATIONAHA.115.018931","volume":"133","author":"A Hartley","year":"2016","unstructured":"Hartley A, Marshall DC, Salciccioli JD, Sikkel MB, Maruthappu M, Shalhoub J. Trends in mortality from ischemic heart disease and cerebrovascular disease in Europe: 1980 to 2009. Circulation. 2016;133:1916\u201326.","journal-title":"Circulation"},{"key":"3469_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","volume":"26","author":"K Kotseva","year":"2019","unstructured":"Kotseva K, De Backer G, De Bacquer D, Ryd\u00e9n L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European society of cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26:824\u201335.","journal-title":"Eur J Prev Cardiol"},{"key":"3469_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jacc.2005.11.028","volume":"47","author":"D Twardella","year":"2006","unstructured":"Twardella D, Rothenbacher D, Hahmann H, W\u00fcsten B, Brenner H. The underestimated impact of smoking and smoking cessation on the risk of secondary cardiovascular disease events in patients with stable coronary heart disease: prospective cohort study. J Am Coll Cardiol. 2006;47:887\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"3469_CR15","unstructured":"Deutsche Herzstiftung. Deutscher Herzbericht 2020. https:\/\/www.herzstiftung.de\/e-paper\/#70. Accessed 16 Oct 2022."},{"key":"3469_CR16","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen M-R, et al. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769\u2013818.","journal-title":"Eur Heart J"},{"key":"3469_CR17","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1093\/eurheartj\/ehw377","volume":"37","author":"A Eisen","year":"2016","unstructured":"Eisen A, Cannon CP, Blazing MA, Bohula EA, Park J-G, Murphy SA, et al. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J. 2016;37:3576\u201384.","journal-title":"Eur Heart J"},{"key":"3469_CR18","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"key":"3469_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.athplu.2022.07.024","volume":"50","author":"I Gouni-Berthold","year":"2022","unstructured":"Gouni-Berthold I, Schaper F, Schatz U, Tabbert-Zitzler A, Fraass U, Sauer S, et al. Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study. Atheroscler Plus. 2022;50:10\u20136.","journal-title":"Atheroscler Plus"},{"key":"3469_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"3469_CR21","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1093\/cvr\/cvz134","volume":"115","author":"T M\u00fcnzel","year":"2019","unstructured":"M\u00fcnzel T. Up in the air: links between the environment and cardiovascular disease. Cardiovasc Res. 2019;115:e144\u20136.","journal-title":"Cardiovasc Res"},{"key":"3469_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajh\/hpx109","volume":"31","author":"RD Brook","year":"2017","unstructured":"Brook RD, Newby DE, Rajagopalan S. Air Pollution and Cardiometabolic Disease: An Update and Call for Clinical Trials. Am J Hypertens. 2017;31:1\u201310.","journal-title":"Am J Hypertens"},{"key":"3469_CR23","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.117.029400","volume":"136","author":"LF Drager","year":"2017","unstructured":"Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S, INCOSACT Initiative (International Collaboration of Sleep Apnea Cardiovascular Trialists). Sleep Apnea and Cardiovascular Disease: Lessons From Recent Trials and Need for Team Science. Circulation. 2017;136:1840\u201350.","journal-title":"Circulation"},{"key":"3469_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/eurjpc\/zwab134","volume":"29","author":"F Vancheri","year":"2022","unstructured":"Vancheri F, Tate AR, Henein M, Backlund L, Donfrancesco C, Palmieri L, et al. Time trends in ischaemic heart disease incidence and mortality over three decades (1990\u20132019) in 20 Western European countries: systematic analysis of the Global Burden of Disease Study 2019. Eur J Prev Cardiol. 2022;29:396\u2013403.","journal-title":"Eur J Prev Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03469-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-023-03469-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03469-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T20:11:50Z","timestamp":1700251910000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-023-03469-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3469"],"URL":"https:\/\/doi.org\/10.1186\/s12872-023-03469-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The KAROLA-I study was approved by the ethics committees of the Universities of Ulm (no. 186\/98) and Heidelberg and by the medical associations of the states of Baden-Wuerttemberg and Hesse. The KAROLA-II study was approved by the ethics committee of the University of Heidelberg (no. 351\/2001). These studies were carried out in accordance with the Declaration of Helsinki, and all methods were used in accordance with the relevant guidelines and regulations. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Wolfgang Koenig reports consulting fees from AstraZeneca, Novartis, Pfizer, The Medicines Company, DalCor Pharmaceuticals, Kowa, Amgen, Corvidia Therapeutics, Daiichi-Sankyo, Genentech, Novo Nordisk, Esperion, OMEICOS, LIB Therapeutics, NewAmsterdam Pharma, TenSixteen Bio; speaker honoraria from Amgen, Novartis, Berlin-Chemie, Sanofi, and Bristol-Myers Squibb, grants and non-financial support from Abbott, Roche Diagnostics, Beckmann, and Singulex, outside the submitted work. The other authors have no competing interests to declare that are relevant to the content of this article. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"428"}}